[ad_1] Only 31% of REWIND trial participants have confirmed cardiovascular disease Lilly said that the company's REWIND mid-term clinical trial, in which TRURITY (name of the ingredient: dulaglutide), a weekly GLP-1 badogue, …
Read More »THE CITY OF TRULEI MEANS THE EXCELLENCE OF CARDIOVASCULAR REDUCTION OF VARIOUS TYPE 2 DIABETES
